Focusing on the future biotechnology (biopharmaceutical) industry, Yin Hong invites company representatives, experts, and scholars for face-to-face exchanges.

On March 31, Party Secretary Yin Hong presided over a symposium on the development of the future biological (biopharmaceutical) industry, inviting some enterprise representatives, experts, and scholars for face-to-face exchanges. Yin Hong emphasized the need to thoroughly implement the spirit of the Fourth Plenary Session of the 20th CPC Central Committee, proactively align with national strategic needs, accurately grasp industry development trends, base efforts on our own strengths, draw on the best practices, fully leverage comparative advantages, focus on tackling niche segments, adapt measures to local conditions to promote high-quality development of our province’s biopharmaceutical industry, and provide strong support for writing a new chapter of Chinese-style modernization in Jiangxi.

Provincial leaders Chen Min, Xia Wenyong, and Shi Ke attended.

“The ‘14th Five-Year’ plan clearly designates the biopharmaceutical industry as an emerging pillar industry, and it has been incorporated into the ‘14th Five-Year’ plan outline and the State Council’s government work report, further highlighting the strategic position of the biopharmaceutical industry. The ‘6+N’ future industry tracks laid out by the CPC Provincial Committee and Provincial Government include biomedicine as one of them. The distinguished guests present are leading enterprise representatives in our province’s biopharmaceutical field and pioneers and participants in the emerging biomedicine track of the future industry. How to cultivate and strengthen our province’s biopharmaceutical industry—this is what we hope to hear everyone’s ideas and suggestions on,” Yin Hong straightforwardly addressed the audience, guiding enterprise representatives and experts to open up discussions and offer advice.

At the symposium, the Provincial Department of Industry and Information Technology reported on the development of the province’s biopharmaceutical industry. Leaders from Renhe Group, China Resources Jiangzhong, Qingfeng Pharmaceutical, Fuxiang Pharmaceutical, Hemei Pharmaceutical, Jiangxi Biological Products Research Institute, Yichun Dahai Turtle, Brain Tiger Technology, and other companies, as well as experts and scholars such as Chen Yeguang, Li Hongliang, and Liang Xinmiao, spoke successively. Participants provided insightful industry trend analysis, combined with their own enterprise realities and research directions, accurately identified issues, and offered candid and practical suggestions. Yin Hong occasionally interjected to ask questions, engaging in interactive exchanges with enterprise leaders and experts, creating a lively and active现场氛围。

Yin Hong emphasized that Jiangxi has a solid foundation and advantages in developing the biopharmaceutical industry. It is necessary to accurately grasp industry development trends, leverage Jiangxi’s resource endowments and industrial base, concentrate resources to strengthen strengths, address weaknesses, and cultivate new areas, focusing on innovation and特色化 development, accelerating industry scale expansion and supply chain extension, and promoting特色化 and差异化 industry development. The modernization of traditional Chinese medicine (TCM) should be strengthened and optimized, leveraging Jiangxi’s rich TCM resources, deepening the secondary development and成果转化 of classic Chinese medicine formulas, supporting enterprises to accelerate innovation and研发 of改良型新药, actively expanding康养 services and other new formats, further enhancing Jiangxi’s TCM brand. It is also crucial to focus on源头科技创新, strengthen the role of企业创新主体, support enterprises in establishing研发中心,中试基地, and验证中心, and focus on tackling frontier fields such as脑机接口,类器官,核医疗, and细胞和基因技术转化, aiming to cultivate new growth points. Additionally, industry element support should be reinforced by充分发挥产业基金引导作用, mobilizing more social and financial capital into the biopharmaceutical sector, further完善柔性引才机制, increasing efforts to attract, cultivate, and retain科技领军人才 and urgently needed专业技术人才, striving to build a healthy产业生态. Principles of高效规范,公平竞争, and充分开放 should be upheld, actively integrating into and serving the construction of a unified national大市场, vigorously supporting innovative products’ clinical application and推广, helping biopharmaceutical companies and products to “go global,” and promoting high-quality development of the industry with stronger保障 and better环境. (Wei Xing, Hai Bo)

Text: Jiangxi Daily All-Media Reporter Wei Xing

Images: Jiangxi Daily All-Media Chief Reporter Hai Bo

Editor: Xu Lin